CHARLES MINARD to Antibodies, Monoclonal
This is a "connection" page, showing publications CHARLES MINARD has written about Antibodies, Monoclonal.
Connection Strength
0.036
-
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors. Pediatr Blood Cancer. 2024 Mar; 71(3):e30817.
Score: 0.036